MedTrace Logo

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

NCT07220135 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-06

No results posted yet for this study

Summary

This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast cancer.

Conditions

Interventions

DRUG

Carboplatin

All of the treatment being received by the study participants during the course of the study is standard of care.

DRUG

Docetaxel

All of the treatment being received by the study participants during the course of the study is standard of care.

DRUG

Trastuzumab (or biosimilar)

All of the treatment being received by the study participants during the course of the study is standard of care.

DRUG

Pertuzumab (or biosimilar)

All of the treatment being received by the study participants during the course of the study is standard of care.

Sponsors & Collaborators

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Yiduo Hu, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-14
Primary Completion
2027-11-14
Completion
2031-05-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07220135 on ClinicalTrials.gov